190 related articles for article (PubMed ID: 31960742)
21. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.
Sørensen GV; Ganz PA; Cole SW; Pedersen LA; Sørensen HT; Cronin-Fenton DP; Garne JP; Christiansen PM; Lash TL; Ahern TP
J Clin Oncol; 2013 Jun; 31(18):2265-72. PubMed ID: 23650417
[TBL] [Abstract][Full Text] [Related]
22. [Cardioprotective treatment during adjuvant cancer therapy].
Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
[TBL] [Abstract][Full Text] [Related]
23. Guidelines and registries: secondary prophylaxis after AMI with emphasis on the use of beta-blockers and ACE inhibitors.
Otterstad JE
Scand Cardiovasc J; 2005 Apr; 39(1-2):10-2. PubMed ID: 16097408
[No Abstract] [Full Text] [Related]
24. Cardioprotection: definition, classification, and fundamental principles.
Kübler W; Haass M
Heart; 1996 Apr; 75(4):330-3. PubMed ID: 8705755
[No Abstract] [Full Text] [Related]
25. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Baumgart P
MMW Fortschr Med; 2006 Mar; 148(11):57, 59-60. PubMed ID: 16612965
[No Abstract] [Full Text] [Related]
26. Heart-protective drugs: a primer. Back to basics on how they work, side effects, interactions.
Heart Advis; 2004 Dec; 7(12):3. PubMed ID: 15779133
[No Abstract] [Full Text] [Related]
27. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
28. Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?
Singh TP; Almond C
J Am Coll Cardiol; 2010 Aug; 56(10):823; author reply 823-4. PubMed ID: 20797500
[No Abstract] [Full Text] [Related]
29. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
31. Aging, cardiotoxicity, and chemotherapy.
Bocchi EA; Avila MS; Ayub-Ferreira SM
Aging (Albany NY); 2019 Jan; 11(2):295-296. PubMed ID: 30668542
[No Abstract] [Full Text] [Related]
32. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.
Cardinale D; Biasillo G; Salvatici M; Sandri MT; Cipolla CM
Expert Rev Mol Diagn; 2017 Mar; 17(3):245-256. PubMed ID: 28092472
[TBL] [Abstract][Full Text] [Related]
33. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
Pokorná Z; Kollárová-Brázdová P; Lenčová-Popelová O; Jirkovský E; Kubeš J; Mazurová Y; Adamcová M; Holečková M; Palička V; Šimůnek T; Štěrba M
Clin Sci (Lond); 2022 Jan; 136(1):139-161. PubMed ID: 34878093
[TBL] [Abstract][Full Text] [Related]
34. Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans.
McMurray J; MacLenachan J; Dargie HJ
J Hypertens; 1991 May; 9(5):393-7. PubMed ID: 1677371
[TBL] [Abstract][Full Text] [Related]
35. What is the recurrence rate of takotsubo syndrome in patients treated with β-blockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers?
Madias JE
Int J Cardiol; 2016 Sep; 219():394-5. PubMed ID: 27362829
[No Abstract] [Full Text] [Related]
36. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
37. Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up.
Gong X; Ding X; Chen H; Li H
J Transl Med; 2018 Dec; 16(1):346. PubMed ID: 30526628
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
39. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
[TBL] [Abstract][Full Text] [Related]
40. Cardiac abnormalities after aneurysmal subarachnoid hemorrhage: effects of β-blockers and angiotensin-converting enzyme inhibitors.
Crago E; Kerris K; Kuo CW; Sherwood P; Hravnak M; Crippen D; Horowitz M
Am J Crit Care; 2014 Jan; 23(1):30-9. PubMed ID: 24382615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
